Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
27Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.71B | $313.75M | $2.39 |
| 2024 | $2.25B | $-278.16M | $-2.18 |
| 2023 | $1.83B | $-440.24M | $-3.52 |
| 2022 | $1.04B | $-1.13B | $-9.30 |
| 2021 | $844.29M | $-852.82M | $-7.20 |
Social Signal Score
Earnings
Thu, Oct 29(in 2 months)
Consensus estimate $1.78 per share
Typical surprise +98.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$1.21 vs $1.63miss
- Thu, Apr 30$1.51 vs $0.87beat
- Thu, Feb 12$0.82 vs $1.16miss
- Thu, Oct 30$2.90 vs $0.56beat
- Thu, Jul 31$0.32 vs $-0.54beat
- Thu, May 1$-0.01 vs $-0.89beat
Estimates and results for ALNY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.52
- Implied price
- $63.34
- Return from $228.65
- -22.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $31.49 — -86.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -35.3% | -32.3% | -29.8% | -27.6% | -25.6% |
| 3.0% | -32.0% | -28.9% | -26.2% | -23.9% | -21.9% |
| 8.0% | -28.7% | -25.4% | -22.6% | -20.2% | -18.1% |
| 13.0% | -25.4% | -22.0% | -19.1% | -16.5% | -14.3% |
| 18.0% | -22.1% | -18.5% | -15.5% | -12.8% | -10.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (5)
- Newsglobenewswire.com·5h ago·Negative
Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm RADNOR, Pa., Aug. 15, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced si…
View source ↗ - Newsbusinesswire.com·21h ago·Negative
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities a…
View source ↗ - Newsglobenewswire.com·2d ago·Negative
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm LOS ANGELES, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations…
View source ↗ - Newsglobenewswire.com·2d ago·Negative
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Continuing Securities Fraud Investigation BENSALEM, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsglobenewswire.com·3d ago·Negative
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗